Comparative Cost-Effectiveness Analysis of Avelumab plus Axitinib Versus Pembrolizumab plus Axitinib, Ipilimumab plus Nivolumab, and Sunitnib for Advanced Renal Cell Carcinoma in the U.k. Perspective.

AuthID
 P-016-70S
8
Author(s)
De Mello, RA
·
Ayoub, E
·
De Almeida Zia, VA
·
Savio, A
·
Pozza, DH
·
Tadokoro, H
·
Teich, N
Tipo de Documento
Article
Year published
2020
Publicado
in Journal of Clinical Oncology, ISSN: 0732-183X
Volume: 38, Número: 6_suppl, Páginas: 689-689
Indexing
Crossref®2
Google Scholar®
Publication Identifiers
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Lista Marked
 Adicionar à lista Marked
Info
At this moment we don't have any links to full text documens.

Um espaço para investigadores e suas Instituições

Links Úteis

Ajuda

© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service